Rizaldy Taslim Pinzon et al., Int. J. Res. Pharm. Sci., 2020, 11 (SPL4), 2891-2895 RĊěĎĊĜ AėęĎĈđĊ IēęĊėēĆęĎĔēĆđ JĔĚėēĆđ Ĕċ RĊĘĊĆėĈč Ďē PčĆėĒĆĈĊĚęĎĈĆđ SĈĎĊēĈĊĘ Published by JK Welfare & Pharmascope Foundation Journal Home Page: www.pharmascope.org/ijrps Unmet needs in Chronic Pain Management: The potential use of Curcumin Rizaldy Taslim Pinzon * , Angela, Andryawan Wahyu Pradana, Vanessa Veronica Department of Neurology, Faculty of Medicine, Duta Wacana Christian University, Yogyakarta, Indonesia Article History: Received on: 07 Nov 2020 Revised on: 10 Dec 2020 Accepted on: 13 Dec 2020 Keywords: Curcuma Longa, Curcumin, Boswellia Serrata, Nsaids, Osteoarthritis, Pain AćĘęėĆĈę The ultimate goal of treatment for osteoarthritis can be achieved by modi- fying disease progression and also symptom reduction. Non-steroidal anti- inϐlammatory drugs and cyclooxygenase-2 inhibitors are inϐlammation and pain management medications that are widely used in osteoarthritis. How- ever, this agent has been linked to have several side effects such as cardio- vascular, gastrointestinal, and kidney. These side effects represent the unmet needs in the safety of existing treatment of osteoarthritis. Such results can be caused by the overlapping functions of COX-1 and COX-2 in physiological and pathophysiological systems. The overlapping functions of COX-1 and COX-2 can be the source of these side effects. The extensive history of the use of curcuminoids and boswellia in pain relief coupled with recent ϐindings shows that this phytochemical can play a direct role in several inϐlammatory pro- cesses and offers strong evidence that this product can slow down cartilage degradation and reduce pain in patients with knee osteoarthritis. Our study indicated that by reducing pain and improving function, while lowering the risk of side effects, curcuminoid formulations might become a useful addi- tion to osteoarthritis patients for pharmacological therapeutic interventions. However, further research is needed with high-quality and large-scale RCT research probably to investigates the synergistic effects of these products with other osteoarthritis treatments. * Corresponding Author Name: Rizaldy Taslim Pinzon Phone: +6281294638229 Email: drpinzon17@gmail.com ISSN: 0975-7538 DOI: https://doi.org/10.26452/ijrps.v11iSPL4.4576 Production and Hosted by Pharmascope.org © 2020 | All rights reserved. INTRODUCTION Osteoarthritis (OA) is one of the main causes of impairment and physical disability in the elderly (Glyn-Jones et al., 2015). An effective man- agement for osteoarthritis remains inconclusive. Typically, osteoarthritis is managed with medica- tion that focuses on reducing pain through palliative measures (Bijlsma et al., 2011; Zhang and Jordan, 2010). There were a signiϐicant group of patients in whom these treatments do not provide adequate pain relief (Lue et al., 2017). The previous studies of treatments that proven can stop or reversing the degenerative process are limited (Chen et al., 2017; Loeser et al., 2012). The ultimate goal of treatment for osteoarthri- tis (OA) can be achieved by modifying disease progression and also symptom reduction. The most widely used agents for the treatment of OA are non-steroidal anti-inϐlammatory medicines (NSAIDs) and selective cyclooxygenase (COX) -2 inhibitors. This drug has been associated with seri- ous side effects (Seager and Hawkey, 2001). Pre- vious reviews have shown that NSAIDs can cause © International Journal of Research in Pharmaceutical Sciences 2891